Saturday, April 24, 2010

Optical Fusion ~ Oclaro, Inc. (Public, NASDAQ:OCLR)

the binary OPTICS play ... TECH and BIO TECH ... BUY $OCLR aka binocular.

optical innovation & photonic philosophy!

CHART LOVERS:
1) stock = uptrend
2) SMA support = good
3) stochastic oversold = reliable
4) consolidating = prudent entry

REV-SPLIT: 1-for-5 on April 29th.

WATCH LIST #1: SEMI-BULLish <~click it.
WATCH LIST #2: MEMO-BULLish (click here)

3 comments:

BUY ON THE DIP said...

RTTNews) - Oclaro, Inc. (OCLR: News ) posted third quarter net income of $205 thousand or $0.00 per share, compared to a net loss of $13.3 million or $0.66 per share in the previous year quarter.

Non-GAAP net income for the quarter was $3.5 million or $0.08 per share, compared to a net loss of $4.4 million or $0.22 per share in the year-ago quarter.

Revenues for the quarter increased to $101.2 million from $41.2 million in the last year quarter.

Analysts polled by Thomson Reuters expected the company to report earnings of $0.01 per share on revenues of $101.01 million. Analysts' estimates typically exclude special items.

The company expects fourth quarter revenues to be in the range of $111 million - $116 million. Six analysts have consensus revenue estimate of $104.84 million for the quarter.

BUY ON THE DIP said...

split and eps raise!


15.09 Up 1.04 (7.40%)

BUY ON THE DIP said...

the temporary trading symbol "OCLRD" will revert to "OCLR" after approximately 20 trading days.

Auriga analyst Chandan Sarkar reiterated a Buy rating for shares of Oclaro, Inc. (Nasdaq: OCLRD) and increased the price target.

Sarkar said that despite the fact that Oclaro, Inc. announced an offering of shares that will dilute existing shareholders earnings per share by about 14%, the company's accelerating fundamentals should push the stock higher.

The analyst noted that Oclaro, Inc. already reported strong fiscal 3rd quarter results and gave strong guidance for the 4th quarter as well.

The Auriga analyst wrote, "while this dilution may reduce the Street’s enthusiasm in the near term, we note the reaction of the recent deal from Finisar (FNSR, Buy) as an indication that accelerating fundamentals in the optical sector are likely to overwhelm the dilution effect. We remain buyers of the stock and are increasing our price target to $4 from $3 based on improving fundamentals driving higher EPS estimates(despite the dilution posed by the deal).